Primary percutaneous coronary intervention is the best treatment of patients with ST elevation myocardial infarction (STEMI). When managing a STEMI patient, our approach must be rapid and aggresive in order to interrupt the pathological process of thrombus formation and stabilization. The therapy must be initiated prior to angiography (pretreatment), continued during the procedure (periprocedur...

Distinguishing ST-elevation myocardial infarction (STEMI) differential diagnoses is more challenging. Myopericarditis is one of these differentials that results from viral involvement of myocardium and pericardium of the heart. Myopericarditis in focal form can mimic acute STEMI in its electrocardiogram (ECG) features and elevated cardiac enzymes. Myocarditis patients may face thrombolytic rela...

A cute coronary syndromes (ACS) include unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation MI (STEMI). Each year in the US, approximately 1,360,000 patients are admitted for ACS, of which 810,000 have an MI and the remainder UA. Approximately two thirds of patients with MI have NSTEMI and the rest have STEMI. Worldwide, more than 3 million people each year a...

Background No proper data on prognosis and management of type-2 diabetic ST elevation myocardial infarction (STEMI) patients with culprit obstructive lesion and multivessel non obstructive coronary stenosis (Mv-NOCS) exist. We evaluated the 12-months prognosis of Mv-NOCS-diabetics with first STEMI vs.to non-diabetics, and then Mv-NOCS-diabetics previously treated with incretin based therapy vs....

INTRODUCTION Patients with ST elevation myocardial infarction (STEMI) require rapid identification and triage to initiate reperfusion therapy. Walk-in STEMI patients have longer treatment times compared to emergency medical service (EMS) transported patients. While effective triage of large numbers of critically ill patients in the emergency department is often cited as the reason for treatment...

Introduction In general, guidelines reflect scientific evidence already acquired and follow, rather than anticipate, new developments in diagnostic and therapeutic practice. This applies to STEMI guidelines. Failure to apply the guidelines is rarely caused by the lack of knowledge of their content. Resistance is invariably due to scepticism as to the true advantage of the treatment proposed, fi...

UNLABELLED Heparin and enoxaparin possess anti-inflammatory properties. We compared the effects of these drugs on inflammatory biomarkers in patients with ST-segment Elevated Myocardial Infarction (STEMI). Thirty four patients with STEMI randomly separated in two groups and received standard doses of heparin and enoxaparin. The serum concentration of Serum Amyloid A (SAA), C-Reactive Protein (C...

At the most severe end of the spectrum of acute coronary syndromes is ST-segment elevation myocardial infarction (STEMI), which usually occurs when a fibrin-rich thrombus completely occludes an epicardial coronary artery. The diagnosis of STEMI is based on clinical characteristics and persistent ST-segment elevation as demonstrated by 12-lead electrocardiography. Patients with STEMI should unde...

Studies have demonstrated an association between QRS duration and long term mortality after myocardial infarction [1,2]. However, there remains a scarcity of data on QRS duration after ST elevation myocardial infarction (STEMI) and its association with mortality.We investigatedwhether QRS duration during STEMI hospitalization could predict 30-day and one yearmortality. A secondary objective was...

The pathogenesis of ST-elevation myocardial infarction (STEMI) involves plaque disruption, platelet aggregation and intracoronary artery thrombus formation. Aspirin is the cornerstone of antiplatelet therapy in patients with STEMI, reducing the risk of recurrent myocardial infarction or death during the acute phase and long term by about one-quarter. Recent large randomized trials have demonstr...